EW - Edwards Lifesciences Corporation
140.81 0.00 (0.00%)
After hours: 5:30PM EDT
| Previous Close | 139.77 |
| Open | 140.14 |
| Bid | 0.00 x 800 |
| Ask | 142.00 x 800 |
| Day's Range | 138.73 - 141.42 |
| 52 Week Range | 100.20 - 156.87 |
| Volume | 806,596 |
| Avg. Volume | 1,246,887 |
| Market Cap | 29.484B |
| Beta | 0.72 |
| PE Ratio (TTM) | 46.24 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Simply Wall St.•10 hours ago
Is Edwards Lifesciences Corporation (NYSE:EW) Excessively Paying Its CEO?
Mike Mussallem is the CEO of Edwards Lifesciences Corporation (NYSE:EW), which has recently grown to a market capitalization of US$29.27b. Recognizing whether CEO incentives are aligned with shareholders is aRead More...
Market Realist•4 days agoWhat Does NovoCure’s Valuation Trend Indicate?
NovoCure’s (NVCR) net financial expenses increased from $2.18 million in the second quarter of 2017 to $2.86 million in the second quarter. NovoCure’s income tax expenses also increased from $3.46 million in the second quarter of 2017 to $5.56 million in the second quarter.
Markit•10 days agoSee what the IHS Markit Score report has to say about Edwards Lifesciences Corp.
Edwards Lifesciences Corp NYSE:EW
Market Realist•14 days agoWhat to Expect for Boston Scientific in Fiscal 2018
During its Q2 2018 earnings release on July 25, Boston Scientific (BSX) updated its fiscal 2018 guidance. The company raised its fiscal 2018 sales guidance and maintained its adjusted EPS guidance at $1.37–$1.41, representing growth of 9%–12%.
- Thomson Reuters StreetEvents•15 days ago
Edited Transcript of EW earnings conference call or presentation 26-Jul-18 9:00pm GMT
Q2 2018 Edwards Lifesciences Corp Earnings Call
Market Realist•17 days agoBoston Scientific’s Q2 2018 Adjusted EPS Exceed Guidance
In the second quarter, Boston Scientific’s adjusted EPS grew 28% YoY (year-over-year) to $0.41, exceeding its guidance of $0.33–$0.35. Boston Scientific’s strong earnings growth in the quarter was due to its strong profit and loss metrics. The company is working on improving cost efficiencies through its end-to-end business by streamlining and automation initiatives, expanding global shared services, and leveraging global sourcing teams. Peers Abbott Laboratories (ABT), Edwards Lifesciences (EW), and Thermo Fisher Scientific (TMO) reported adjusted EPS growth of 17.7%, 30.5%, and 19. ...
Markit•19 days agoSee what the IHS Markit Score report has to say about Edwards Lifesciences Corp.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Market Realist•20 days agoAbbott Laboratories’ Stock Price Performance in July
On July 24, Abbott Laboratories (ABT) ended the trading day at $64.40 per share. Currently, the stock is trading higher than its 50-day moving average of $62.45 and its 200-day moving average of $60.75.
Markit•24 days agoSee what the IHS Markit Score report has to say about Edwards Lifesciences Corp.
Edwards Lifesciences Corp NYSE:EW
Market Realist•24 days agoWall Street Raises Target Price on ABT after Strong Q2 Earnings
Abbott Laboratories' Q2 Results: What Drove Its Robust Growth?Analysts’ recommendations for ABT
- Zacks•24 days ago
Edwards Lifesciences (EW) Q2 Earnings Beat, Revenues Miss
Edwards Lifesciences (EW) gains from THVT strength on continued therapy adoption across all geographies in Q2.
Market Realist•25 days agoEW Fell 5.8% in After-Hours Trading despite Strong Q2 Results
EW Fell 5.8% in After-Hours Trading despite Strong Q2 ResultsEdwards Lifesciences reports its Q2 2018 earnings
- Associated Press•25 days ago
Edwards Lifesciences: 2Q Earnings Snapshot
On a per-share basis, the Irvine, California-based company said it had net income of $1.32. Earnings, adjusted for non-recurring gains, were $1.24 per share. The results surpassed Wall Street expectations. ...
- Zacks•26 days ago
Medical Product Earnings Lineup for Jul 26: BAX, EW & More
Streak of regulatory developments and deep R&D focus are likely to drive the Medical Product industry this earnings season. Here we take a quick look at four Medical Product majors that are going to release earnings results.
- Market Realist•27 days ago
What to Expect from Edwards Lifesciences’ Q2 2018 Results
Edwards Lifesciences is slated to release its Q2 2018 earnings results on July 26 after the market closes. For Q1 2018, Edwards Lifesciences missed sales estimates. EW stock had fallen ~1.8% on April 24, when the company released its Q1 2018 earnings results.
InvestorPlace•28 days ago7 Healthcare Stocks That Are Coming to Life
U.S. equities continue to churn near major technical resistance levels — S&P 500 2,800 and 25,000 on the Dow Jones Industrial Average — as investors digest a heavy serving of headlines.
Markit•last monthSee what the IHS Markit Score report has to say about Edwards Lifesciences Corp.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting EW. Over the last one-month, outflows of investor capital in ETFs holding EW totaled $729 million.
- Zacks•last month
Will Edwards' (EW) Steady Overall Growth Drive Q2 Earnings?
Edwards Lifesciences (EW) expected to gain from strength in all business segments and geographies in Q2.
- Zacks•last month
Here's Why You Should Add Edwards Lifesciences (EW) Now
We are upbeat about Edwards Lifesciences' (EW) strong transcatheter valve sales in the domestic market as well as overseas.
Markit•last monthSee what the IHS Markit Score report has to say about Edwards Lifesciences Corp.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- Investor's Business Daily•last month
Major Indexes Fall Broadly, Caterpillar Sells Off; These 2 Retailers Sink Especially Hard
The major indexes showed darker action with a broad decline Wednesday, but volume is mixed so far. Utilities advanced. Airlines fell hard.
Markit•last monthSee what the IHS Markit Score report has to say about Edwards Lifesciences Corp.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting EW. Over the last one-month, outflows of investor capital in ETFs holding EW totaled $3.13 billion.
- Investopedia•2 months ago
12 Stocks That Can Lead in a Rocky Second Half
Against an economic landscape marked by rising interest rates and growing trade tensions, Goldman Sachs Group Inc. ( GS) believes that companies with strong balance sheets are particularly well-suited to ride out the turbulence.
Markit•2 months agoSee what the IHS Markit Score report has to say about Edwards Lifesciences Corp.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- CNBC Videos•last month
Opening Bell, July 20, 2018
Ringing today's opening bells are Edwards Lifesciences with Jen Hyde, patient advocate, celebrating its 60th anniversary of founding at the NYSE, and Discovery Inc. with Luke Tipple, TV host and marine biologist, celebrating Shark Week 2018 at the Nasd...
